Sara Nass

Dr. Sara Nass

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2017 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
GDGiulia Donvito
Giulia Donvito
SNSara Nass
Sara Nass
JWJenny Wilkerson
Jenny Wilkerson
ZCZachary A Curry
Zachary A Curry
LSLesley D Schurman
Lesley D Schurman
ALAron H Lichtman
Aron H Lichtman
A great need exists for the development of new medications to treat pain resulting from various disease states and types of injury. Given that the endogenous cannabinoid (that is, endocannabinoid) system modulates neuronal and immune cell function, both of which play key roles in pain, therapeutics targeting this system hold promise as novel analgesics. Potential therapeutic targets include the cannabinoid receptors, type 1 and 2, as well as biosynthetic and catabolic enzymes of the endocannabinoids N-arachidonoylethanolamine and 2-arachidonoylglycerol. Notably, cannabinoid receptor agonists as well as inhibitors of endocannabinoid-regulating enzymes fatty acid amide hydrolase and monoacylglycerol lipase produce reliable antinociceptive effects, and offer opioid-sparing antinociceptive effects in myriad preclinical inflammatory and neuropathic pain models. Emerging clinical studies show that ‘medicinal’ cannabis or cannabinoid-based medications relieve pain in human diseases such as cancer, multiple sclerosis, and fibromyalgia. However, clinical data have yet to demonstrate the analgesic efficacy of inhibitors of endocannabinoid-regulating enzymes. Likewise, the question of whether pharmacotherapies aimed at the endocannabinoid system promote opioid-sparing effects in the treatment of pain reflects an important area of research. Here we examine the preclinical and clinical evidence of various endocannabinoid system targets as potential therapeutic strategies for inflammatory and neuropathic pain conditions.

1 November 2014 in Brain, Behavior, and Immunity
Verified
Journal Article
Closed access
MCMolly S. Crowe
Molly S. Crowe
SNSara Nass
Sara Nass
KGKristin M. Gabella
Kristin M. Gabella
SKSteven G. Kinsey
Steven G. Kinsey

1 October 2018 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
KTKristen R. Trexler
Kristen R. Trexler
SNSara Nass
Sara Nass
MCMolly S. Crowe
Molly S. Crowe
JGJoshua D. Gross
Joshua D. Gross
MJMargaret S. Jones
Margaret S. Jones
SKSteven G. Kinsey
Steven G. Kinsey

1 May 2020 in Neurobiology of Stress
Verified
Journal Article
Open access
Jason ParisJason Paris
Jason Paris
PLPhilippe Liere
Philippe Liere
SKSarah Kim
Sarah Kim
FMFakhri Mahdi
Fakhri Mahdi
MBMeagan E. Buchanan
Meagan E. Buchanan
KHKurt F. Hauser
Kurt F. Hauser
Pregnane steroids, particularly allopregnanolone (AlloP), are neuroprotective in response to central insult. While unexplored in vivo, AlloP may confer protection against the neurological dysfunction associated with human immunodeficiency virus type 1 (HIV-1). The HIV-1 regulatory protein, trans-activator of transcription (Tat), is neurotoxic and its expression in mice increases anxiety-like behavior; an effect that can be ameliorated by progesterone, but not when 5α-reduction is blocked. Given that Tat's neurotoxic effects involve mitochondrial dysfunction and can be worsened with opioid exposure, we hypothesized that Tat and/or combined morphine would perturb steroidogenesis in mice, promoting neuronal death, and that exogenous AlloP would rescue these effects. Like other models of neural injury, conditionally inducing HIV-1 Tat in transgenic mice significantly increased the central synthesis of pregnenolone and progesterone's 5α-reduced metabolites, including AlloP, while decreasing central deoxycorticosterone (independent of changes in plasma). Morphine significantly increased brain and plasma concentrations of several steroids (including progesterone, deoxycorticosterone, corticosterone, and their metabolites) likely via activation of the hypothalamic-pituitary-adrenal stress axis. Tat, but not morphine, caused glucocorticoid resistance in primary splenocytes. In neurons, Tat depolarized mitochondrial membrane potential and increased cell death. Physiological concentrations of AlloP (0.1, 1, or 10 nM) reversed these effects. High-concentration AlloP (100 nM) was neurotoxic in combination with morphine. Tat induction in transgenic mice potentiated the psychomotor effects of acute morphine, while exogenous AlloP (1.0 mg/kg, but not 0.5 mg/kg) was ameliorative. Data demonstrate that steroidogenesis is altered by HIV-1 Tat or morphine and that physiological AlloP attenuates resulting neurotoxic and psychomotor effects.

1 May 2020 in Brain, Behavior, & Immunity - Health
Verified
Journal Article
Open access
SNSara Nass
Sara Nass
YHYun K. Hahn
Yun K. Hahn
VMVirginia D. McLane
Virginia D. McLane
Neil VarshneyaNeil Varshneya
Neil Varshneya
MDM. Imad Damaj
M. Imad Damaj
KHKurt F Hauser
Kurt F Hauser
HIV-1 selectively disrupts neuronal integrity within specific brain regions, reflecting differences in viral tropism and/or the regional differences in the vulnerability of distinct neuronal subpopulations within the CNS. Deficits in prefrontal cortex (PFC)-mediated executive function and the resultant loss of behavioral control are a particularly debilitating consequence of neuroHIV. To explore how HIV-1 disrupts executive function, we investigated the effects of 48 h, 2 and/or 8 weeks of HIV-1 Tat exposure on behavioral control, synaptic connectivity, and neuroimmune function in the anterior cingulate cortex (ACC) and associated cortico-basal ganglia (BG)-thalamocortical circuitry in adult, Tat transgenic male mice. HIV-1 Tat exposure increased novelty-exploration in response to novel food, flavor, and environmental stimuli, suggesting that Tat triggers increased novelty-exploration in situations of competing motivation (e.g., drive to feed or explore vs. fear of novel, brightly lit open areas). Furthermore, Tat induced adaptability in response to an environmental stressor and pre-attentive filtering deficits. The behavioral insufficiencies coincided with decreases in the inhibitory pre- and post-synaptic proteins, synaptotagmin 2 and gephyrin, respectively, in the ACC, and alterations in specific pro- and anti-inflammatory cytokines out of 23 assayed. The interaction of Tat exposure and the resultant time-dependent, selective alterations in CCL4, CXCL1, IL-12p40, and IL-17A levels in the PFC predicted significant decreases in adaptability. Tat decreased dendritic spine density and cortical VGLUT1 inputs, while increasing IL-1β, IL-6, CCL5, and CCL11 in the striatum. Alternatively, IL-1α, CCL5, and IL-13 were decreased in the mediodorsal thalamus despite the absence of synaptic changes. Thus, HIV-1 Tat appears to uniquely and systematically disrupt immune regulation and the inhibitory and excitatory synaptic balance throughout the ACC-BG-thalamocortical circuitry resulting in a loss of behavioral control.

1 January 2021 in Neuroscience Letters
Verified
Journal Article
Closed access
MOMichael Ohene-Nyako
Michael Ohene-Nyako
SNSara Nass
Sara Nass
YHYun K. Hahn
Yun K. Hahn
PKPamela E. Knapp
Pamela E. Knapp
KHKurt F Hauser
Kurt F Hauser